Challenges in Modulating Insulin Receptor Signalling As a Therapeutic Strategy for Cancer

Overview

Journal Indian J Med Res

Specialty General Medicine

Date 2018 Sep 1

PMID 30168483

Authors

Priya Srinivas

Madhavan Radhakrishna Pillai

Affiliations

Soon will be listed here.

References

Winter P, Sarosiek K, Lin K, Meggendorfer M, Schnittger S, Letai A . RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014; 7(357):ra122. PMC: 4353591. DOI: 10.1126/scisignal.2005301. View

Ekyalongo R, Yee D . Revisiting the IGF-1R as a breast cancer target. NPJ Precis Oncol. 2017; 1. PMC: 5687252. DOI: 10.1038/s41698-017-0017-y. View

Palorini R, Votta G, Balestrieri C, Monestiroli A, Olivieri S, Vento R . Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J Cell Biochem. 2013; 115(2):368-79. DOI: 10.1002/jcb.24671. View

Beckwith H, Yee D . Minireview: Were the IGF Signaling Inhibitors All Bad?. Mol Endocrinol. 2015; 29(11):1549-57. PMC: 5414672. DOI: 10.1210/me.2015-1157. View

Wen Y, Liu W, Sun H, Ge X, Shi Z, Wang M . IGF-1-mediated PKM2/β-catenin/miR-152 regulatory circuit in breast cancer. Sci Rep. 2017; 7(1):15897. PMC: 5698474. DOI: 10.1038/s41598-017-15607-y. View

Chan J, Hackel B, Yee D . Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. Mol Cancer Ther. 2017; 16(7):1324-1334. PMC: 5518922. DOI: 10.1158/1535-7163.MCT-16-0685. View

Assefa B, Mahmoud A, Pfeiffer A, Birkenfeld A, Spranger J, Arafat A . Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxid Med Cell Longev. 2018; 2017:3035184. PMC: 5750484. DOI: 10.1155/2017/3035184. View

Janssen J, Varewijck A . IGF-IR Targeted Therapy: Past, Present and Future. Front Endocrinol (Lausanne). 2015; 5:224. PMC: 4275034. DOI: 10.3389/fendo.2014.00224. View

Enguita-German M, Fortes P . Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 2014; 6(10):716-37. PMC: 4209417. DOI: 10.4254/wjh.v6.i10.716. View

10.

Stamateris R, Sharma R, Kong Y, Ebrahimpour P, Panday D, Ranganath P . Glucose Induces Mouse β-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor. Diabetes. 2016; 65(4):981-95. PMC: 5314707. DOI: 10.2337/db15-0529. View

11.

Sharma P, Kumar S . S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells. Indian J Med Res. 2018; 147(6):545-551. PMC: 6118145. DOI: 10.4103/ijmr.IJMR_403_17. View

12.

Hammoudi N, Riaz Ahmed K, Garcia-Prieto C, Huang P . Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer. 2011; 30(8):508-25. PMC: 4013402. DOI: 10.5732/cjc.011.10267. View

13.

Chan J, LaPara K, Yee D . Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. Oncogene. 2016; 35(32):4235-43. PMC: 4982805. DOI: 10.1038/onc.2015.488. View

14.

Kabat G, Kim M, Lane D, Zaslavsky O, Ho G, Luo J . Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. Eur J Cancer Prev. 2018; 27(3):261-268. DOI: 10.1097/CEJ.0000000000000435. View

15.

Candelaria P, Rampoldi A, Harbuzariu A, Gonzalez-Perez R . Leptin signaling and cancer chemoresistance: Perspectives. World J Clin Oncol. 2017; 8(2):106-119. PMC: 5385432. DOI: 10.5306/wjco.v8.i2.106. View

16.

Amitani M, Asakawa A, Amitani H, Inui A . The role of leptin in the control of insulin-glucose axis. Front Neurosci. 2013; 7:51. PMC: 3619125. DOI: 10.3389/fnins.2013.00051. View

17.

Christopoulos P, Msaouel P, Koutsilieris M . The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015; 14:43. PMC: 4335664. DOI: 10.1186/s12943-015-0291-7. View